Bicycle Therapeutics (BCYC) Q3 2024 earnings summary

Executive summary

• Focused on developing Bicycle® molecules for oncology, with key candidates zelenectide pevedotin, BT5528, BT7480, and BT1718 in advanced clinical trials, and reported 45% overall response rates for zelenectide pevedotin and BT5528 in metastatic urothelial cancer with differentiated safety profiles.

• Advanced radiopharmaceuticals pipeline with first human imaging data validating MT1-MMP as a novel cancer target and outlined strategy for next-generation radiopharmaceuticals.

• Announced updated clinical results for lead programs at major conferences and consolidated discovery research to the UK headquarters to prioritize high-value programs.

• Collaborations with Bayer, Novartis, Ionis, and Genentech continue to provide significant non-dilutive funding and milestone opportunities.

• Cash and cash equivalents reached $890.9 million as of September 30, 2024, providing expected financial runway into the second half of 2027.

Financial highlights

• Cash and cash equivalents were $890.9 million as of September 30, 2024, up from $526.4 million at year-end 2023, mainly due to a $544.1 million private placement and share option exercises.

• Research and development expenses increased to $48.3 million in Q3 2024, driven by expanded clinical activities, zelenectide pevedotin development, and one-time severance costs.

• General and administrative expenses rose to $18.3 million in Q3 2024, reflecting higher headcount and share-based compensation.

• Net loss for Q3 2024 was $50.8 million, or $(0.74) per share, compared to $49.9 million, or $(1.26) per share, in Q3 2023.

• Collaboration revenues for Q3 2024 were $2.7 million, down from $5.4 million in Q3 2023, primarily due to the completion of obligations under the Ionis agreement.

Outlook and guidance

• Cash runway expected to fund operations and capital expenditures for at least 12 months from the filing date and into the second half of 2027, excluding a $31.7 million UK R&D tax credit received in October 2024.

• Anticipates continued increases in R&D and G&A expenses as clinical programs advance and pipeline expands.

• Additional data updates for zelenectide pevedotin in other tumor types and in combination with pembrolizumab are planned by year end; BT5528 combination results with nivolumab expected in 2025.

• Expects to seek additional funding in the future to support ongoing and planned development activities.